CORRESP Filing
Rapport Therapeutics, Inc.
Date: July 7, 2025 · CIK: 0002012593 · Accession: 0001193125-25-156162
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-288444
Letter
Re: Rapport Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 Filed July 1, 2025 File No. 333-288444 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “ Act ”), Rapport Therapeutics, Inc. (the “ Company ”) hereby requests that the effective date of the above-referenced registration statement (the “ Registration Statement ”) be accelerated to July 9, 2025, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Stephanie A. Richards at (617) 570-1927. If you have any questions regarding this request, please contact Stephanie A. Richards of Goodwin Procter LLP at (617) 570-1927.
VIA EDGAR July 7, 2025 United States Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549
Sincerely,
RAPPORT THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP VIA EDGAR July 7, 2025 United States Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Rapport Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 Filed July 1, 2025 File No. 333-288444 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “ Act ”), Rapport Therapeutics, Inc. (the “ Company ”) hereby requests that the effective date of the above-referenced registration statement (the “ Registration Statement ”) be accelerated to July 9, 2025, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Stephanie A. Richards at (617) 570-1927. If you have any questions regarding this request, please contact Stephanie A. Richards of Goodwin Procter LLP at (617) 570-1927. Sincerely, RAPPORT THERAPEUTICS, INC. /s/ Abraham N. Ceesay Abraham N. Ceesay Chief Executive Officer cc: Troy Ignelzi, Rapport Therapeutics, Inc. Kingsley L. Taft, Goodwin Procter LLP Stephanie A. Richards, Goodwin Procter LLP